Genocea Biosciences Inc (NASDAQ:GNCA)

0.9363
Delayed Data
As of 4:00pm ET
 +0.0013 / +0.14%
Today’s Change
0.79
Today|||52-Week Range
6.78
-19.28%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$84.2M

Company Description

Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Contact Information

Genocea Biosciences, Inc.
Cambridge Discovery Park
Cambridge Massachusetts 02140
P:(617) 876-8191
Investor Relations:

Employees

Shareholders

Mutual fund holders8.04%
Individual stakeholders40.66%
Other institutional14.21%

Top Executives

Chip ClarkPresident, CEO, CFO, Director & CAO
Jessica Baker FlechtnerChief Scientific Officer
Eric S. HoffmanChief Business Officer
John E. BishopSenior Vice President-Pharmaceutical Sciences
Narinder SinghSenior VP-Pharmaceutical Sciences & Manufacturing